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Nicotinic acetylcholine receptors (nAChRs) containing 6
and 4 subunits are expressed by dorsal root ganglion neurons
and have been implicated in neuropathic pain. Rodent models
are often used to evaluate the efficacy of analgesic compounds,
but species differences may affect the activity of some nAChR
ligands. A previous candidate -conotoxin-based therapeutic
yielded promising results in rodent models, but failed in human
clinical trials, emphasizing the importance of understanding
species differences in ligand activity. Here, we show that human
and rat 6/34 nAChRs expressed in Xenopus laevis oocytes
exhibit differential sensitivity to-conotoxins. Sequencehomo-
logy comparisons of human and rat64 nAChR subunits indi-
cated that 6 residues forming the ligand-binding pocket are
highly conserved between the two species, but several residues
of 4 differed, including a Leu–Gln difference at position 119.
X-ray crystallography of -conotoxin PeIA complexed with the
Aplysia californica acetylcholine-binding protein (AChBP)
revealed that binding of PeIA orients Pro13 in close proximity
to residue 119 of the AChBP complementary subunit. Site-
directed mutagenesis studies revealed that Leu119 of human
4 contributes to higher sensitivity of human 6/34
nAChRs to-conotoxins, and structure–activity studies indi-
cated that PeIA Pro13 is critical for high potency. Human and
rat 6/34 nAChRs displayed differential sensitivities to
perturbations of the interaction between PeIA Pro13 and res-
idue 119 of the 4 subunit. These results highlight the poten-
tial significance of species differences in 64 nAChR phar-
macology that should be taken into consideration when
evaluating the activity of candidate human therapeutics in
rodent models.
Nicotinic acetylcholine receptors (nAChRs)5 are ligand-
gated ion channels formed by the pentameric assembly of indi-
vidual subunits. There are 16 genes in mammals that encode
these subunits and are represented by the Greek symbols
1–7, 9, 10, 1–4, , , and  (1). nAChRs are expressed
by neurons in both the central and peripheral nervous systems
and are involved in diverse physiological processes (2), includ-
ing fast synaptic transmission (3), the modulation of neu-
rotransmitter release (4–10), and numerous immunological
processes (11, 12).
Native nAChRs containing the 6 subunit are broadly clas-
sified into two subtype categories: those that contain the 2
subunit and those that contain the 4 subunit. The 62* sub-
type (the asterisk denotes the potential presence of additional
subunits in native receptors) has a limited distribution profile in
the nervous system but is abundantly expressed in certain
regions of the brain and spinal cord (13–19). The 64* sub-
type probably has an even more restricted expression profile.
Functional evidence for 64* nAChR expression in sensory
neurons of rat and mouse dorsal root ganglia (DRG) has been
demonstrated (20, 21), although their functional role in these
cells is mostly unknown.
DRG contain neurons that perform a wide range of sensory
functions, including proprioception and the detection of harm-
ful or painful stimuli. Recent evidence suggests that 64
nAChRs represent a new molecular target for the treatment of
neuropathic pain. Development of neuropathic pain-like symp-
toms has been shown to be inversely correlated with CHRNA6
expression levels in the DRG of mice (21). Strains with high
levels of CHRNA6 expression show lower levels of mechanical
allodynia in several neuropathic and inflammatory pain
models, and those with low levels of CHRNA6 expression are
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more susceptible to developing neuropathic pain. Intriguingly,
CHRNA6 null mice show no analgesic responses to nicotine,
whereasmice with a gain-of-functionmutation show increased
analgesic responses. In addition, a history of chronic pain syn-
dromes in humans correlates with levels of CHRNA6 expres-
sion (21).
Rodent models of neuropathic pain are often used to study
mechanisms of nociception as well as to evaluate potential
therapeutics that can modulate the transmission and per-
ception of pain. However, rodent models can be compro-
mised by a number of species-related factors that complicate
translation of results obtained in rodent studies to human
clinical trials. One of these factors is the difference in ligand
sensitivity between human and rodent receptors and ion
channels.
Conotoxins are small peptides found in the venom of carniv-
orous marine snails of the Conus genus and are used by these
mollusks to capture prey. -Conotoxins (-Ctxs) belong to a
subclass of conotoxins and are antagonists of nAChRs. Some
-Ctxs are capable of distinguishing among the various nAChR
subtypes (22). -Ctx Vc1.1 (23, 24) is an example of a ligand
developed as a treatment for neuropathic pain that showed
promising results in rodentmodels but failed to produce similar
levels of analgesia in human clinical trials. It was later demon-
strated that decreased sensitivity of human versus rat nAChRs
to Vc1.1might have contributed to this outcome. It is therefore
important to determine how species differences influence
receptor sensitivity to ligands. To this end, we have examined
the interaction of human and rat 64 nAChRs with -Ctxs to
elucidate molecular determinants of ligand potency for this
receptor subtype. Through structure–activity studies of PeIA,
site-directed mutagenesis of 6 and 4 subunits, X-ray crystal-
lography, and NMR studies of PeIA, we have identified impor-
tant molecular determinants of -Ctx potency for human
and rat 64 nAChRs. The information obtained from these
studies offers important insights into the pharmacology of
64 nAChRs and might facilitate the development of selec-
tive ligands that interact with this potential neuropathic pain
target.
Results
-Conotoxins PeIA, PnIA, and TxIB inhibit human6/34
nAChRsmore potently than rat6/34 nAChRs
We chose three -Ctxs with different sequences to as-
sess their ability to distinguish between human and rat
6/34 nAChRs, namely PeIA (26), PnIA (27), and TxIB
(28) (Fig. 1). When tested on human and rat 6/34
nAChRs heterologously expressed in Xenopus oocytes, we
found that all three -Ctxs showed higher potency on the
human homolog. The IC50 values for inhibition of human
6/34 nAChRs were 15-fold lower for PeIA, 50-fold
lower for PnIA, and 30-fold lower for TxIB than those
obtained for rat 6/34 nAChRs (Fig. 2 (A–C) and Table 1).
These results suggest that intrinsic differences between
human and rat 6/34 nAChRs confer differential sensitiv-
ities to -Ctxs.
Sequences of human and rat6 subunits are highly
conserved, but several residues of4 that form the
ligand-binding pocket differ
A sequence alignment of human and rat 6 subunits indi-
cates that the extracellular domains are similar, and in fact res-
idues that form the canonical ligand-binding pocket are strictly
conserved (Fig. S1). The closest residue to the ligand-binding
pocket that differs in the 6 sequences is located at position
177. In humans, this residue is Ile, but in rat, a Val is present.
Analysis of the 4 subunits revealed more significant sequence
differences occurring at positions 110, 118, and 119. In human
4, these residues are Leu, Val, and Leu, and in rat, they are Val,
Ile, and Gln. These three nonconserved residues are all located
in the ligand-binding pocket and might contribute to the spe-
cies differences in-Ctxs potencies for inhibition of human and
rat 6/34 nAChRs.
The4 subunit is amajor determinant of the species
differences in PeIA, PnIA, and TxIB potencies for human versus
rat6/34 nAChRs
Aseries of experimentswas performed to determinewhether
differences in the amino acid sequences of human and rat 4
subunits are important for -Ctx potency for 6/34
nAChRs. In the first experiment, one group of oocytes was
injected with cRNAs encoding human 6/3 and rat 4 sub-
units, and another groupwas injectedwith cRNAs encoding rat
6/3 and human 4 subunits. The potencies for PeIA, PnIA,
and TxIB were then reassessed on these hybrid combinations
with the hypothesis that the IC50 values for receptors composed
of human (H)6/3 and rat (R)4 subunits would be similar to
R6/3R4 nAChRs. Likewise, the IC50 values for inhibition of
R6/3H4 and H6/3H4 nAChRs would also be similar.
Consistentwith these predictions, the IC50 curves for inhibition
of H6/3R4 by PeIA, PnIA, and TxIB are right-shifted
toward those for R6/3R4 nAChRs (Fig. 3 (A–C) and Table
2). Conversely, the IC50 curves for inhibition of R6/3H4 are
left-shifted toward H6/3H4 nAChRs (Fig. 3 (A–C) and
Table 2). These results indicate that the4 subunit is an impor-
tant determinant of the species differences in-Ctx potency for
inhibition of 6/34 nAChRs.
As additional evidence in support of the importance of the4
subunit for conferring differential -Ctx potencies, we tested
the same three -Ctxs on human and rat 6/323 nAChRs.
Figure1. Sequence comparisonof select 4/7 framework-Ctxs.Conotox-
ins are classified into various subclasses based on the number of cysteine
residues present in the sequence and the number of amino acid residues
between them (63). Peptides of the -Ctx subclass contain two disulfide-
connected pairs of cysteines. Thus, for example, -Ctxs with four residues
between Cys2 and Cys3 and seven between Cys8 and Cys16 belong to the 4/7
framework subclass. Residues in black are variable, and those in red are con-
served among this -Ctx set. The disulfide bonds between Cys residues are
depicted with lines. *, C-terminal amidation.
Determinants of-Ctx potency for64 nAChRs
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In the 623 nAChR, the canonical -Ctx ligand-binding site
is located at the interface between the 6 and 2 subunits. We
aligned the sequences of human and rat 2 subunits and found
that residues known to interact with -Ctxs are strictly con-
served (29, 30), and in fact only three conservative differences
were noted in the entire extracellular ligand-binding domain
sequence (Fig. S2). When we tested PeIA on human and rat
6/323 nAChRs, we found that the IC50 values for the two
Table 1
IC50 values for inhibition of human and rat 6/34 nAChRs by PeIA,
PnIA, and TxIB
Values in parentheses indicate the 95% CI of the data obtained from at least four
oocytes per IC50 determination.
-Ctx
IC50
Human
6/34
Rat
6/34
nM
PeIA 9.9 (8.2–11.9) 154 (143–166)
PnIA 149 (135–164) 8,456 (5,419–13,290)
TxIB 402 (338–477) 10,000
Figure 2. -Ctxs distinguish between human and rat 6/34
nAChRs. X. laevis oocytes expressing human or rat 6/34 nAChRs were
subjected to TEVC electrophysiology, and the IC50 values were deter-
mined for inhibition of ACh-evoked currents by PeIA (A), PnIA (B), and TxIB
(C). Values are provided in Table 1. Error bars, S.D. from at least four
oocytes for each IC50 determination.
Figure3.Potencyof-CtxPeIAon6/34nAChRs formedbyswitching
species subunits. Different combinations of H and R 6/3 and 4 subunits
were expressed in X. laevis oocytes and subjected to TEVC electrophysiology
as described under “Experimental procedures.” A–C, inhibition curves for
ACh-evoked currents by PeIA, PnIA, and TxIB were obtained from oocytes
expressing human 6/3 with rat 4 subunits (closed circles) or rat 6/3
with human 4 subunits (open circles). Data for inhibition of human
(dashed red) and rat (dashed green) 6/34 nAChRs by PeIA, PnIA, and
TxIB were previously presented and shown for ease of comparison. Values
are provided in Table 2. Error bars, S.D. from at least four oocytes for each
IC50 determination.
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species were nearly identical (Fig. 4A and Table 3). Similar
results were obtained for PnIA and TxIB (Fig. 4 (B and C) and
Table 3). In all comparisons, a 2-fold difference in the IC50
values was found.
Site-directedmutagenesis of human4 implicates residue 119
as a critical determinant of high-potency PeIA binding to
human6/34 nAChRs
The high sequence similarity of human and rat 6 and 4
subunits allowed us to focus on select residues that might con-
tribute to the species differences in -Ctx potency for human
and rat 6/34 nAChRs. We used site-directed mutagenesis
to generate receptor mutants where nonconserved residues of
6 and 4 subunits were switched to the residues found in the
homologous positions of the other species and then assessed
the effects of thesemutations on6/34 nAChR sensitivity to
PeIA. In the 6 subunit, there is an Ile-Val difference between
human and rat sequences, respectively, at position 177. We
found that when Ile177 of human 6 was switched to Val, the
IC50 value of PeIA was similar to the value obtained for human
6/34 nAChRs (Fig. 5A; Table 4), indicating that this residue
contributes very little to the species difference in PeIA potency.
Next, residues Leu110, Val118, and Leu119 of human 4 were
individually switched to Val, Ile, and Gln, respectively, and
expressed with human 6/3 subunits. Similar to the 6I177V
mutation, L110V and V118I mutations in the 4 subunit had
very little impact on the IC50 value of PeIA (Fig. 5A andTable 4).
However, when the 6/3 subunit was expressed with the
4L119Q mutant subunit, the IC50 value increased by10-fold,
and the curve shifted to the right toward that of rat 6/34
nAChRs (Fig. 5A and Table 4). To determine whether residues
118 and 119 might play a combined role in PeIA binding, we
made a double V118I,L119Q mutant human 4 subunit and
reassessed the potency of PeIA. The sensitivity of the
6/34V118I,L119Q mutant to PeIA was similar to that of the
6/34L119Q single mutant, indicating no added effect with
the combined mutations (Fig. 5A and Table 4). To further
assess the influence of position 119 on PeIA potency, we made
an additional human 4 mutant where Leu119 was changed to
Phe, the residue found in the homologous positions of human
and rat 2 subunits (Fig. S2). The IC50 value for inhibition of
6/34L119F mutant nAChRs by PeIA was similar (2-fold
difference) to the value for receptors with native 4 subunits
(Fig. 5A and Table 4). Mutation experiments were also per-
formed for rat 6/34 nAChRs and, similar to the results
found for human receptor 6V177I, 4V110L, 4I118V, and
4Q119F mutations, had very little effect on the sensitivity of rat
Figure 4.-Ctxs PeIA, PnIA, and TxIB donot distinguish betweenhuman
and rat 6/323 nAChRs. X. laevis oocytes expressing human or rat
6/323 nAChRs were subjected to TEVC electrophysiology as described
under “Experimental procedures,” and the IC50 values were determined for
inhibitionofACh-evokedcurrentsbyPeIA (A), PnIA (B), andTxIB (C). Values are
provided in Table 3. Error bars, S.D. from at least four oocytes for each IC50
determination.
Table 2
PeIA IC50 values for inhibition of 6/34 nAChRs formed by mixing
human and rat 6/3 and 4 subunits
Values in parentheses indicate the 95%CI of the data obtained from four oocytes per
IC50 determination. H, human; R, rat.
nAChR IC50
nM
H6/3H4 9.9 (8.2–11.9)a
H6/3R4 68.1 (59.8–77.6)
R6/3R4 154 (143–166)a
R6/3H4 37.5 (30.1–46.2)
a Data from Table 1 shown for ease of comparison.
Table 3
IC50 values for inhibition of human and rat 6/323 nAChRs by
PeIA, PnIA, and TxIB
Values in parentheses indicate the 95%CI of the data obtained from four oocytes per
IC50 determination.
-Ctx
IC50
Human Rat
nM
PeIA 16.0 (14.2–18.1) 16.3 (13.2–20.2)
PnIA 2.8 (2.0–3.8) 3.3 (3.0–3.6)
TxIB 291 (255–332) 207 (175–244)
Determinants of-Ctx potency for64 nAChRs
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6/34 nAChRs to PeIA relative to nonmutated receptors
(Fig. 5B and Table 4). However, in contrast to the results
obtained with human 6/34L119Q and 6/34V118I,L119Q
nAChRs,mutation of the homologous residues of rat4 had no
effect on the sensitivity of rat6/34 nAChRs to PeIA (Fig. 5B
and Table 4). The results of these receptor mutation experi-
ments indicate that position 119 of human 4 plays an impor-
tant role in the interaction between PeIA and human 6/34
nAChRs, but other factors appear to be involved in determining
the lower potency of PeIA for rat 6/34 nAChRs.
X-ray crystallography of PeIA complexedwith Aplysia
californica AChBP reveals close spatial proximity of residue
Pro13 of PeIA toMet119 of the AChBP complementary subunit
The marine mollusk Aplysia californica expresses a water-
soluble protein called AChBP that functions to modulate ACh-
mediated synaptic transmission in this organism (31). X-ray
crystallography studies of the AChBP have been used to eluci-
date binding interactions between ligands and nAChRs (32–
35). Several high-resolution crystal structures have been
reported for the AChBP complexed with -Ctxs (36–39) but
not with PeIA. To gain further insights into the interactions
between PeIA and human 64 nAChRs, we performed X-ray
crystallography of the AChBP complexed with PeIA. The
resulting 2.34 Å resolution structure of the AChBP–PeIA com-
plex is shown in Fig. 6 (A–C). An examination of the complex
reveals that PeIA residue Pro13 is oriented toward the comple-
mentary subunit and in close proximity toMet119 of theAChBP
(Fig. 6C). In the 64 receptor complex, the complementary
subunit corresponds to the 4 subunit. A sequence alignment
of the human 4 ligand-binding domain with the AChBP
indicates that Met119 of the AChBP is homologous with
human 4Leu-119 (Fig. S3). The proximity of Met119 of the
AChBP to Pro13 of PeIA suggests that an interaction might
occur between these two residues, and functional analysis of
human 6/34L119M mutant nAChRs expressed in oocytes
indicates that a Met in position 119 influences PeIA activity
(Fig. S3).
Structure–activity studies identify Pro13 as important for PeIA
potency on human and rat6/34 nAChRs
The crystal structure of PeIA complexed with the AChBP
suggests that PeIA residue Pro13 probably interacts with the 4
subunit. Therefore, we used analogs of PeIA where Pro13 was
substituted with different amino acids to probe the interaction
between this residue and position 119 of the 4 subunit. Four
analogs, including [P13A]PeIA and [P13O]PeIA, described
previously (40), as well as two newly synthesized analogs,
[P13Q]PeIA and [P13R]PeIA, were tested on human 6/34
nAChRs expressed in oocytes and evaluated for changes in
potencies relative to native PeIA. Substitution of Pro13 with
4-hydroxyproline (Hyp) orGln resulted in small decreases (3-
fold) in the potency of PeIA for human 6/34 nAChRs (Fig.
7A and Table 5). However, substitution of Pro with Ala or Arg
resulted in more substantial decreases in potency by 7- and
20-fold, respectively (Fig. 7A and Table 5). The rank order
potency of these analogs is [P13O]PeIA  [P13Q]PeIA 
[P13A]PeIA  [P13R]PeIA. The IC50 values for these analogs
were then determined for rat 6/34 nAChRs. Although all
analogs showed reduced potency, relative to native PeIA, there
were differences in the magnitude of the changes for rat
compared with human 6/34 nAChRs. The potency of
Figure 5. Residue Leu119 of human 4 is an important determinant of PeIA potency for human 6/34 nAChRs. X. laevis oocytes expressing mutant
6/34nAChRswere subjected toTEVCelectrophysiologyasdescribedunder “Experimental procedures,” and the IC50 values for inhibitionofACh-evokedcurrents
by PeIA were determined. A, concentration–response curves for inhibition of human 6I177V/34, 6/34L110V, 6/34V118I, 6/34L119F 6/34L119Q (blue),
and 6/34V118I,L119Q nAChRs by PeIA. B, concentration–response curves for inhibition of rat 6V177I/34, 6/34V110L, 6/34I118V, 6/34Q119L (blue),
6/34Q119F, and 6/34I118V,Q119L nAChRs by PeIA. Values are provided in Table 4. Data for inhibition of human (dashed red) and rat (dashed green) 6/34
nAChRs by PeIAwere previously presented and shown for ease of visual comparison. Error bars, S.D. from at least four oocytes for each IC50 determination.
Table 4
Effect of6/3 and4 subunit mutation on the IC50 values for inhibi-
tion of human and rat 6/34 nAChRs by PeIA
Values in parentheses indicate the 95%CI of the data obtained from four oocytes per
IC50 determination. Note that only the human 4L119Q mutation substantially (3-
fold) affects PeIA potency.
nAChR IC50
nM
Human
6/34 9.9 (8.2–11.9)a
6I177V/34 14.6 (12.3–17.3)
6/34L110V 15.7 (13.9–17.8)
6/34V118I 10.6 (8.6–13.0)
6/34L119Q 94.3 (87.8–101)
6/34L119F 13.0 (10.7–15.7)
6/34V118I,L119Q 70.7 (66.1–75.6)
Rat
6/34 154 (143–166)a
6V177I/34 88.7 (76.3–103)
6/34V110L 96.3 (85.9–108)
6/34I118V 119 (105–134)
6/34Q119L 200 (166–250)
6/34Q119F 241 (212–274)
6/34I118V,Q119L 116 (101–133)
a Data from Table 1 shown for ease of comparison.
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[P13A]PeIA for rat 6/34 nAChRs was only 3-fold lower
(Fig. 7B and Table 5) compared with the 10-fold lower potency
observed for the human homolog. Analogs [P13Q]PeIA and
[P13R]PeIA showed 53- and 335-fold lower potencies for
rat 6/34 compared with3- and20-fold lower potencies
(Fig. 7B and Table 5), respectively, for human 6/34
nAChRs. Substitution of Pro13 with Hyp resulted in 4-fold
lower potency on rat 6/34 nAChRs (Fig. 7B and Table 5)
similar to the 3-fold decrease observed for human 6/34
nAChRs. Thus, the rank order potency for these analogs on
rat 6/34 nAChRs is [P13A]PeIA  [P13O]PeIA 
[P13Q]PeIA  [P13R]PeIA.
Figure 6. X-ray crystallography of PeIA complexedwith theA. californicaAChBP. A and B, cartoon rendition of the AChBP–PeIA structure shown from the
side (A) and from the top or extracellular view (B). The AChBP is shown in green, and PeIA is shown in red. Residues 1–10 of PeIA are recognized as forming two
-helices split between residues His5 and Pro6. An electron density for a fifth PeIA molecule was observed but omitted because the clarity of the electron
density was such that only the peptide backbone structure could be determined accurately, not the side-chain positions. C, cartoon rendition of two subunits
showing the location of residuesAla110, Val118, andMet119 (yellow) in the complementary () subunit (cyan) and Leu177 (yellow) of the principal subunit (green).
Note that the side chain of Met119 is oriented toward PeIA, whereas the side chains of Ala110 and Val118 are oriented away fromPeIA. Pro13 of PeIA is depicted as
a stick model. The distances between the -carbon of PeIA Pro13 and the -sulfur and -carbon of Met119 were 3.6 and 5.4 Å, respectively.D, cartoon rendition of the
AChBP–PeIA structurewith positions 177 of the principal () subunit and 110, 118, and 119 of the complementary () subunitmutated to the residues found in the
homologouspositionsofhuman6and4subunits, respectively.Thedistancebetweenthe-carbonofPeIAPro13andthe-carbonofLeu119of thecomplementary
subunit was 4.0 Å. Note that position 177 is located outside the ligand-binding pocket and therefore unlikely to directly interact with PeIA.
Figure 7. PeIA residue Pro13 is an important determinant of PeIA potency for 6/34 nAChRs. X. laevis oocytes expressing human or rat 6/34
nAChRs were subjected to TEVC electrophysiology as described under “Experimental procedures,” and the IC50 values were determined for inhibition of
ACh-evoked currents by analogs of PeIA. A, concentration–response curves for inhibition of human 6/34 nAChRs by analogs of PeIA. B, concentration–
response curves for inhibition of rat6/34 nAChRs by analogs of PeIA. Values are provided in Table 5. Error bars, S.D. from at least four individual oocytes for
each IC50 determination. Data for inhibition of human 6/34 (dashed red) and rat 6/34 nAChRs (dashed green) by PeIA were presented previously and
shown for ease of visual comparison.
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NMR analysis of PeIA demonstrates that the backbone
structure and side-chain positions are unchangedwith Ala
substitution of Pro13
One possible effect of substituting PeIA Pro13 with other
amino acids is that changes in the tertiary structure of the pep-
tide might occur. To determine whether large changes in the
backbone structure or repositioning of the side chains could
account for the loss of potency observed with the P13A substi-
tution, we performed NMR analysis on [P13A]PeIA and com-
pared its structure with that of native PeIA. A pattern of nega-
tive secondary shifts across residues Ala7–Val10 indicated the
presence of a short helix (Fig. 8A) in agreement with the NMR
solution structure of PeIA determined previously (41). Analysis
of the secondaryH shifts, as calculated by subtracting random
coil H shifts from the peptide H shifts, suggested a slight
difference in [P13A]PeIA across the C-terminal section of the
peptide from residue Asn11 to Cys16. Therefore, we calculated
the three-dimensional solution NMR structure of [P13A]PeIA
to determine whether there were changes in the overall struc-
ture of the peptide. A total of 98 distance restraints were deter-
mined from NOESY data collected in aqueous solution at 290
K, along with 14 dihedral angle restraints. Restraints for two
hydrogen bonds (Val10 HN–Pro6 CO and His12 HN–Cys8 CO)
were also added based upon preliminary structures and amide
chemical shift/temperature coefficients (42). The ensemble of
the 20 lowest-energy structures overlay well (root mean square
deviation 0.60  0.16 Å for the backbone atoms) (Fig. 8B). A
comparison with native PeIA revealed no apparent effect of the
P13A substitution on either peptide backbone (root mean
square deviation 1.02 Å, backbone atoms) or side-chain orien-
tation (Fig. 8C). These structural data suggest that the losses of
potency observedwith the P13A-substituted analog are not due
to large changes in tertiary structure of the peptide.
A direct interaction between PeIA Pro13 and position 119 of4
is involved in the binding of PeIA to human6/34 nAChRs
The close proximity of PeIA Pro-13 and Met-119 of the
AChBP complementary subunit and the lower potencies
Figure 8. NMR indicates that Ala substitutionof Pro13 hasminimal impact onpeptide structure.A, secondaryH shifts of native PeIA and the [P13A]PeIA
analog in aqueous solution at 290 K. The horizontal axis represents the sequence of PeIA. B, backbone superposition of the 20 lowest-energy structures of
[P13A]PeIA.C, ribbon diagramof [P13A]PeIA (blue) overlaidwith PeIA (gray, PDB obtained fromConoServer (25)). An-helix is present from residue 7 to 10, and
the side chains of residue 13 are shown as sticks.
Table 5
IC50 values for inhibition of human and rat 6/34 nAChRs by analogs of PeIA
Values in parentheses indicate the 95% CI of the data obtained from four oocytes per IC50 determination. Log(IC50 ratio) log(analog/PeIA).
-Ctx
Human Rat
IC50
Log
(IC50 ratio) IC50
Log
(IC50 ratio)
nM nM
PeIA 9.9 (8.2–11.9)a 154 (143–166)a
[P13O]PeIA 32.6 (28.2–37.7) 0.5 688 (540–876) 0.7
[P13A]PeIA 73.3 (66.8–80.5) 0.9 381 (317–456) 0.4
[P13Q]PeIA 34.0 (26.1–44.4) 0.5 8,231 (5,784–11,710) 1.7
[P13R]PeIA 188 (159–222) 1.3 51,780 (29,710–90,270) 2.5
a Data from Table 1 shown for ease of comparison.
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observed with the PeIA analogs suggest that Pro-13 and posi-
tion 119 of the 4 subunit might directly interact. Double
mutant paradigmswhere ligandmutants are paired with recep-
tor mutants can be used to examine pairwise interactions
between ligand and receptor residues. Therefore, to determine
whether an interaction occurs between Pro-13 and position
119, we tested the PeIA analogs on the 4 subunit mutants and
found that the IC50 value of [P13A]PeIA for inhibition of
human 6/34L119Q mutant receptors was higher than
the values obtained for the 6/34:[P13A]PeIA and 6/
34L119Q:PeIA combinations (Fig. 9A and Table 6). Similar
results were found when [P13Q]PeIA and [P13R]PeIA were
tested on the 6/34L119Q mutant (Fig. 9 (B and C) and Table
6). In each case, the -fold increase in the IC50 value for each
double peptide–receptor mutant combination was larger than
the sum of the each individual mutant IC50. These data are
consistent with a direct interaction between residue 13 of PeIA
and residue 119 of human 4.
Position 119 of human and rat4 and human2 subunits
interacts differentially with residue 13 of-Ctxs to influence
binding
The results shown in Fig. 5 indicate that mutating residue
119 of 4 to Phe has no impact on the potency of PeIA for
human or rat 6/34 nAChRs. However, we note that there
are some differences in the potencies of the Pro13-substituted
PeIA analogs on human 6/34 and those previously found
for rat 6/323 nAChRs. PeIA shows a 7-fold loss of
potency on human 6/34 nAChRs with the P13A substitu-
tion (Fig. 7A and Table 5), yet rat 6/323 nAChRs are
equally sensitive to PeIA and the P13A analog (40). Further-
more, PnIA, which also has a Pro in position 13, is significantly
more potent on human 6/323 than 6/34 nAChRs, in
contrast to PeIA, which is equally potent on both subtypes (Fig.
3 (A and B) and Table 3). These differences in potency suggest
that the binding interactions between Pro13 of-Ctxs and posi-
tion 119 of the 2 and 4 subunits may not be equivalent.
Therefore, we tested [P13A]PeIA for its ability to inhibit the
6/34L119F mutant and compared the IC50 value with those
for human 6/34 and 6/323 nAChRs. The Leu to Phe
mutation in position 119 of 4 had no effect on the loss of PeIA
potency for 6/34 nAChRs caused by the P13A substitution
(Fig. 10A and Table 6). Similar results were observed with the
[P13R]PeIA analog (Fig. 10A and Table 6). In each case, the
higher IC50 values for inhibition of the6/34L119Fmutant by
[P13A]PeIA and [P13R]PeIAwere similar to those for 6/34
nAChRs. By contrast, the IC50 values of [P13A]PeIA and
Figure 9. Structure–activity studies identify a critical interaction
between PeIA Pro13 and 4Leu-119 for high potency on human 6/34
nAChRs. X. laevis oocytes expressing humannAChRswere subjected to TEVC
electrophysiology as described under “Experimental procedures,” and the
IC50 values were determined for inhibition of ACh-evoked currents by-Ctxs.
A–C, concentration–response curves for inhibition of 6/34L119Q mutant
nAChRs by [P13A]PeIA, [P13R]PeIA, and [P13Q]PeIA. The IC50 values are pro-
vided in Table 6. Error bars, S.D. from at least four individual oocytes for each
IC50 determination. Dashed lines, data previously presented and shown for
ease of visual comparison.
Table 6
IC50 values for inhibition of human 6/34 mutants and 6/32
nAChRs by -Ctxs
Values in parentheses indicate the 95% CI of the data obtained from at least four
oocytes per IC50 determination. The log(IC50 ratio) was calculated by dividing the
IC50 value for each nAChR:-Ctx combination (nAChR:PeIA analog, nAChRmutant:-Ctx, or nAChR mutant:PeIA analog) by the IC50 for the WT:WT combi-
nation; negative values indicate higher potency, and positive values indicate lower
potency. The -fold change in IC50 nAChR:PeIA analog/WT:WT, nAChRmutant:
-Ctx/WT:WT, or nAChR mutant:PeIA analog/WT:WT. Note that for the latter
comparison, the IC50 values are greater than the sum of each single nAChRmutant
or PeIA analog combination (nAChR:PeIA analog/WT:WT or nAChR mutant:
PeIA/WT:WT). Differences between IC50 values are considered substantial if0.5
log units or3-fold. WT, WT receptor or WT -Ctx.
nAChR:-Ctx IC50
Log
(IC50 ratio)
Change
in IC50
nM -fold
6/34:PeIA 9.9 (8.2–11.9)a
6/34L119Q:PeIA 94.3 (87.8–101)a 1.0 10
6/34:[P13A]PeIA 73.3 (66.8–80.5)a 0.9 7
6/34L119Q:[P13A]PeIA 244 (223–267) 1.4 25
6/34:[P13R]PeIA 188 (159–222)a 1.3 19
6/34L119Q:[P13R]PeIA 365 (331–403) 1.6 37
6/34:[P13Q]PeIA 34.0 (26.1–44.4)a 0.5 3
6/34L119Q:[P13Q]PeIA 363 (287–460) 1.6 37
6/34L119F:PeIA 13.0 (10.7–15.7)a 0.1 1
6/34L119F:[P13A]PeIA 56.7 (52.8–61.3) 0.8 6
6/34L119F:[P13R]PeIA 208 (170–256) 1.3 21
6/323:PeIA 16.0 (14.2–18.1)a
6/323:[P13A]PeIA 30.6 (25.5–36.7) 0.3 2
6/323:[P13R]PeIA 8.9 (8.2–9.6) 0.3 0.6
6/34:PnIA 149 (135–164)a
6/34L119F:PnIA 94.6 (87.9–102) 0.2 0.6
a Data previously shown for ease of comparison.
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[P13R]PeIA on human 6/323 nAChRs were unchanged
relative to the values for native PeIA (Fig. 10B and Table 6).
Additionally, there were no differences between the IC50 values
of PnIA for the 6/34L119F mutant and 6/34 nAChRs
(Fig. 10C and Table 6). These results are in contrast to those
found when PnIA was tested on rat 6/34Q119F mutant
receptors; the IC50 value was 12-fold lower than the IC50
value for rat6/34 nAChRs (Fig. 11A andTable 7). Similarly,
the IC50 value for PnIA was 9-fold lower on the rat
6/34Q119Lmutant (Fig. 11A andTable 7), also in contrast to
the lack of effect observed for human 6/34L119Q nAChRs
(Fig. 10C and Table 6). Nevertheless, similar to the results
obtained for the human 6/34L119F mutant, rat 6/
34Q119F nAChRs were less sensitive to [P13R]PeIA and
[P13Q]PeIA than to native PeIA (Fig. 11B and Table 7). These
results indicate that with respect to ligand potency, the interac-
tions between residue 13 of -Ctxs and position 119 of 2 and
4 subunits are not equivalent. Furthermore, the interaction
between PeIA Pro13 and position 119 of the  subunit is
involved in the ability of PnIA to discriminate between rat, but
not human, 6/34 and 6/323 nAChRs.
Discussion
Compounds expected to have analgesic properties are often
tested in rodentmodels of pain with the expectation (and hope)
that the results will be translatable to humans.However, several
factors can influence whether a drug that is effective in rodents
will also produce the same efficacy in humans. Some of these
factors include bioavailability, metabolism, and, importantly,
sensitivity of the molecular target to the compound of interest.
Species differences in the amino acid sequences of target mol-
ecules can have substantial effects on ligand potency. For exam-
ple, -Ctx Vc1.1 was an effective analgesic in rodent models of
neuropathic pain but failed to show similar efficacy in human
clinical trials (23–25). A single amino acid difference between
human and rat 9 nAChR subunits was later shown to confer
higher potency for rat over human 910 nAChRs, a potential
analgesic target of Vc1.1 (43).
We recently reported that human 34 nAChRs are essen-
tially insensitive to the 34 antagonist -Ctx AuIB but show
increased sensitivity to other -Ctxs compared with rat 34
nAChRs (44, 45). Understanding how species differences influ-
ence ligand potency for 64 nAChRs is potentially critical for
the successful development of analgesic ligands, with minimal
off-target effects, for treating neuropathic pain in humans. In
this study, we report that human and rat 6/34 nAChRs
show differential sensitivity to -Ctxs PeIA, PnIA, and TxIB
(Fig. 2 andTable 1). To evaluate the contributions of the6 and
4 subunits to the higher -Ctx potency for human 6/34
nAChRs, we expressed human 6/3 subunits with rat 4 sub-
units in Xenopus oocytes and found that the IC50 curves for
inhibition of this hybrid combination by all three tested -Ctxs
are substantially right-shifted toward those for R6/3R4
nAChRs (Fig. 3 and Table 2). Likewise, when rat 6/3 is
expressed with human 4, the IC50 curves are left-shifted
toward those for H6/3H4 nAChRs (Fig. 3 and Table 2).
These experiments suggest that intrinsic properties of human
4 are important determinants of higher -Ctx potency for
64 nAChRs. Complementary experiments were also con-
ducted on oocytes expressing human or rat 6/323
nAChRs to determine whether the 2 subunit might also pro-
duce species differences in -Ctx potency. However, the IC50
values for PeIA, PnIA, and TxIB differed by less than 2-fold,
indicating that species differences between human and rat con-
tribute to the differential sensitivities of 6/34, but not
6/323, nAChRs to these -Ctxs (Fig. 4 and Table 3).
There are several factors that might contribute to the higher
-Ctx potency for human 6/34 nAChRs. First, there are
Figure 10. -Ctx potency for human 6/34 nAChRs is not affected by
mutationof Leu119 toPhe.X. laevisoocytes expressinghumannAChRswere
subjected to TEVC electrophysiology as described under “Experimental pro-
cedures,” and the IC50 values were determined for inhibition of ACh-evoked
currents by -Ctxs. A, concentration–response curves for inhibition of
6/34L119F mutant nAChRs by [P13A]PeIA and [P13R]PeIA. B, con-
centration–response curves for inhibition of 6/323 nAChRs by
[P13A]PeIA and [P13R]PeIA. Note that P13A and P13R substitutions of PeIA
have very little effect on PeIA potency for inhibition of the 6/323 sub-
type. C, concentration–response curves for inhibition of 6/34L119F
mutant and6/323 nAChRs by PnIA. Note thatmutating Leu119 of the4
subunit to Phe has no effect on PnIA potency for 6/34 nAChRs. The IC50
values are provided in Table 6. Error bars, S.D. from at least four individual
oocytes for each IC50 determination. The ACh concentrations used were 300
M for6/34,6/34L119Q, and6/34L119F nAChRs and 100M for the
6/323 subtype. Dashed lines, data previously presented and shown for
ease of visual comparison.
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three nonconserved residues of human and rat4 subunits that
form the ligand-binding pocket andmight directly interactwith
ligands potentially affecting ligand affinity. Nonconserved res-
idues outside the ligand-binding pocket might also contribute,
albeit indirectly, to ligand affinity by altering the tertiary struc-
ture of the subunit. This, in turn, might affect the way the sub-
units associate with each other to create the ligand-binding
surfaces.Here,we have examined the effect of substituting non-
conserved residues of human 6 and 4 subunits with residues
found in the homologous positions of the respective rat sub-
units. These residues include Ile177 of human 6 and Leu110,
Val118, and Leu119 of human 4 (Fig. S1). We observed that
mutation of Ile177 to Val in the 6 sequence has no effect on
PeIA potency, but substantial effects were found with muta-
tions of human 4. When Leu119 was mutated to Gln, the
potency of PeIA for 6/34 nAChRs was reduced by 10-
fold, but when Leu119 was mutated to Phe, the potency was
unchanged (Fig. 5A and Table 4). PeIA potency was also
reduced by4-fold when Leu119 was mutated to Met (Fig. S3).
Additional mutations of human 4 were made to determine
whether other nonconserved residues contributed to species
differences in PeIA potency.We found that the potency of PeIA
Figure 11. Structure–activity studies of PnIAandPeIAdemonstrate interactionbetweenposition119of rat4and-Ctxs. X. laevisoocytes expressing
rat nAChRs were subjected to TEVC electrophysiology as described under “Experimental procedures,” and the IC50 values were determined for inhibition of
ACh-evoked currents by -Ctxs. A, concentration–response curves for inhibition of 6/34Q119L and 6/34Q119F mutant nAChRs by PnIA. The IC50 values
are provided in Table 7. Error bars, S.D. from at least four individual oocytes for each IC50 determination.Dashed lines, data previously presented for PnIA on rat
6/323 and 6/34 nAChRs and shown for ease of visual comparison. B, representative current traces showing inhibition of 6/34Q119F and
6/34Q119L by 10 M PnIA. Traces in black are control responses, and those in red are responses in the presence of PnIA. C, response analysis of [P13Q]PeIA
and [P13R]PeIA inhibition of ACh-evoked currentsmediated bymutant6/34Q119L and6/34Q119F nAChRs. The currentsmediated by6/34Q119L and
6/34Q119F nAChRs in the presence of 10M [P13Q]PeIAwere 82 5% (n 4) and 69 5% (n 5), respectively, of control responses andwere significantly
larger than those obtained for 6/34 nAChRs (47  5% (n  4)). The responses of 6/34Q119L and 6/34Q119F nAChRs after exposure to 10 M
[P13R]PeIA were also significantly larger than those obtained with 6/34 nAChRs under the same conditions (98  2% (n  4) and 86  4% (n  4),
respectively, of control responses compared with 58 3% (n 4) for 6/34 nAChRs). Statistical significance was determined using an analysis of variance
and Fisher’s least significant difference test (***, p	 0.001; ****, p	 0.0001). Error bars, S.D. for the indicated number of individual replicates.D, representative
current traces for inhibition ofmutant6/34Q119L and6/34Q119F nAChRs by the indicated PeIA analogs. Traces in black are control responses, and those
in red are responses in the presence of the -Ctxs.
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was not affected by either L110V or V118I mutations. A double
mutant combining the V118I and L119Q mutations was then
made to determine whether an interaction between Ile and Gln
could potentially influence PeIA potency, but no further
decrease in PeIAs IC50 value, compared with that for the
6/34L119Q single mutant, was observed. It should be noted
that mutation of Leu to Val and Val to Ile are conservative
changes that might not result in easily observable effects on
PeIA potency. Nevertheless, these experiments demonstrate
that of the three nonconserved ligand-binding pocket residues
between human and rat 4, only the Leu–Gln difference at
position 119 contributes to the higher affinity of PeIA for
human 6/34 nAChRs. Similar experiments were con-
ducted for rat 6/34 nAChRs, but strikingly, we found that
none of the mutations in rat subunits substantially changed the
potency of PeIA, including the 4Q119L mutation (Fig. 5B and
Table 4). Therefore, we took a different approach to further
examine the interaction of PeIA with 6/34 nAChRs.
X-ray crystallography studies of PeIA complexed with the
AChBP showed that PeIA Pro-13 is in close proximity to Met-
119 of the complementary subunit. Based on this observation,
we synthesized analogs of PeIA where Pro13 was substituted
with Hyp, Gln, Ala, or Arg to determine whether Pro13 and
position 119 of the 4 subunit interacted (Fig. 7 (A and B) and
Table 5). Substitution of Pro13 with Hyp or Gln reduced the
potency of PeIA for human 6/34 nAChRs but by only
3-fold. More substantial decreases in potency resulted when
Pro13 was substituted with Ala (7-fold) or Arg (20-fold).
Although all four PeIA analogs showed reduced potencies for
rat6/34 nAChRs, they did not show the samemagnitude of
change found for human 6/34 nAChRs. Themost substan-
tial differences were found with the P13Q and P13R substitu-
tions (Fig. 7 (A and B) and Table 5). [P13Q]PeIA showed a
53-fold reduction in potency for rat 6/34 nAChRs, much
larger than the 3-fold reduction observed for human
6/34. The P13R substitution rendered rat 6/34
nAChRs essentially insensitive to PeIA and resulted in a335-
fold reduction in potency relative to native PeIA. The
[P13A]PeIA analog showed the largest reduction in potency for
human (7-fold) compared with rat (3-fold) 6/34
nAChRs (Fig. 7 (A and B) and Table 5). The results obtained
with these PeIA analogs reveal additional species differences
in ligand binding and suggest that the ligand-binding sur-
faces of human and rat 6/34 nAChRs are intrinsically
different despite having highly conserved ligand-binding
domain sequences.
Additional support for an interaction between PeIA Pro13
and position 119 of the4 subunit was obtained by determining
the potencies of the PeIA analogs on the human 6/34L119Q
(Fig. 8 (A–C) and Table 6) and rat 6/34Q119L mutants (Fig.
11B and Table 7). These double ligand–receptor mutant com-
binations resulted in additional reductions in PeIA potency for
both species, lending support for a direct interaction between
PeIA Pro13 and position 119 of the 4 subunit.
To ensure that the reduced potencies observedwith the PeIA
analogswere not the result of changes in the overall structure of
the peptide due to substitution of rigid Pro, we examined the
structure of [P13A]PeIA and compared it with that of the native
peptide usingNMR.Although somedifferences in theHshifts
of residues 10–15 were observed, the overall backbone struc-
ture appeared unchanged relative to the native peptide (Fig. 8).
Furthermore, the orientations of the Pro13 and Ala13 side
chainswere similar in the native peptide and the analog, respec-
tively, suggesting that the losses in potencies observed with
the PeIA analogs are not due to repositioning of the side
chains. Last, the PeIA potency differences observed for human
6/34 and 6/34L119Q nAChRs are not due to changes in
the potency or efficacy of the agonist acetylcholine (Fig. S4).
Zhangsun et al. showed that mutation of Phe119 to Gln in the
rat 2 subunit results in increased potency of LvIA for 32
nAChRs (46). By contrast, we found that for human 6/34
nAChRs, mutation of 4Leu-119 to Gln decreased the potency of
PeIA by 10-fold, and mutation to Phe had no effect (Fig. 5A
and Table 4). These results initially suggested that Phe can sub-
stitute for Leu in position 119 with respect to PeIA binding and
might offer a “protective” effect against the reduction in poten-
cies observed with the [P13A]PeIA and [P13R]PeIA analogs
because the IC50 values for [P13A]PeIA and [P13R]PeIA on
human 6/323 nAChRs are unchanged relative to native
PeIA (Fig. 10B and Table 6). However, when [P13A]PeIA and
[P13R]PeIA were tested on the human 6/34L119F mutant,
the loss of PeIA potency was similar to that found for nonmu-
tated receptors (Fig. 10A and Table 6). Additionally, the rat
6/34Q119F mutant as well as the 6/34Q119L mutant also
showed lower sensitivity to [P13R]PeIA and [P13Q]PeIA (Fig.
11 (B and C) and Table 7). These results suggest that position
119 of human 2 and 4 and rat 4 are not equivalent with
respect to ligand binding even when the same amino acid is
present (by mutation) in the receptor. Additional evidence for
the nonequivalency of position 119 for ligand binding was
obtained with PnIA. There was no difference in PnIA potency
between human 6/34 and the 6/34L119F mutant and,
consequently, no change in the ability of PnIA to discriminate
between human 6/323 and 6/34 nAChRs (Fig. 10C
Table 7
IC50 values for inhibition of rat 6/34 mutants and 6/323
nAChRs by -Ctxs
Values in parentheses indicate the 95% CI of the data obtained from at least four
oocytes per IC50 determination. The log(IC50 ratio) was calculated by dividing the
IC50 value for each nAChR:-Ctx combination (nAChR:PeIA analog, nAChRmutant:-Ctx, or nAChR mutant:PeIA analog) by the IC50 for the WT:WT combi-
nation; negative values indicate higher potency, and positive values indicate lower
potency. The -fold change in IC50 nAChR:PeIA analog/WT:WT, nAChRmutant:
-Ctx/WT:WT, or nAChR mutant:PeIA analog/WT:WT. Differences between
IC50 values are considered substantial if0.5 log units or3-fold. WT,WT recep-
tor or WT -Ctx.
nAChR:-Ctx IC50
Log
(IC50 ratio)
Change
in IC50
nM -fold
6/34:PeIA 154 (143–166)a
6/34Q119L:PeIA 203 (166–250)a 0.1 1
6/34:[P13Q]PeIA 8,231 (5,784–11,710)a 1.7 53
6/34Q119L:[P13Q]PeIA 10,000 1.8 65
6/34:[P13R]PeIA 51,780 (29,710–90,270)a 2.5 336
6/34Q119L:[P13R]PeIA 10,000 1.8 65
6/34Q119F:PeIA 241 (212–274)a 0.2 2
6/34Q119F:[P13Q]PeIA 35,170 (24,000–51,520) 2.4 228
6/34Q119F:[P13R]PeIA 10,000 1.8 65
6/323:PnIA 3.3 (3.0–3.6)a
6/34:PnIA 8,456 (5,419–13,290)a
6/34Q119L:PnIA 942 (744–1,192) 1.0 0.1
6/34Q119F:PnIA 684 (533–878) 1.1 0.1
a Data previously shown for ease of comparison.
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and Table 6). However, PnIA showed substantially increased
potency on rat 6/34Q119F and 6/34Q119L mutants (Fig.
11A and Table 7). In summary, the results of these receptor and
ligandmutation studies argue for species- and subtype-specific
ligand–receptor interactions that are context-dependent.
Therefore, we urge caution directly comparing ligand–receptor
interactions among species as well as generalizing results
obtained for different nAChR subtypes of the same species.
Furthermore, the fact that both PeIA and PnIA have a Pro res-
idue in position 13 but only PnIA shows differential potencies
for mutant rat, but not human, 6/34 nAChRs also argues
for caution when generalizing interactions between receptor
residues and residues of different -Ctxs.
The 64 subtype is an emerging, novel target for the treat-
ment of neuropathic pain, but very little information is available
concerning the interaction of ligands with this subtype at the
molecular level. Ligands selective for 64 nAChRs might be
critical to avoid off-target effects that can occur due to interac-
tions with closely related subtypes, particularly 34. In this
study, we have identified 4Leu-119 as an important residue of
the human 4 subunit that interacts with -Ctxs. To our
knowledge, this is the first report to functionally identify this
key interaction. The information contained in this study might
ultimately guide the design of ligands that target 64 nAChRs
for the treatment of neuropathic pain.
Experimental procedures
Oocyte two-electrode voltage-clamp electrophysiology
Xenopus laevis frogs were obtained from Xenopus Express
(RRID:SCR_016373). Protocols for the isolation of oocytes
from the frogs were approved by the University of Utah insti-
tutional animal care and use committee. Methods describing
the preparation of cRNA encoding human and rat nAChR sub-
units for expression of nAChRs in Xenopus oocytes have been
described previously (44). The human and rat6/3 constructs
were generated by replacing the extracellular ligand-binding
domain of the 3 subunit with that of the 6 subunit as
described previously (47, 48). These constructs were used
because injection of oocytes with cRNAs encoding human 6
and4 subunits resulted in no functionally expressed receptors
across multiple donors (data not shown). The rat 6/3 con-
struct was used for comparison and has been previously shown
to display similar sensitivities to -Ctxs compared with non-
mutated 6 (49). Preliminary experiments varying the ratio of
rat 6/3 to 4 subunit cRNAs by 10:1 or 1:10 to favor the
formation of receptors with different stoichiometries had no
effect on PeIA potency (data not shown). In all subsequent
experiments, the oocytes were injected with equal ratios of
cRNA for all subunit combinations.
Data analysis
Concentration–response data were obtained from a mini-
mum of four oocytes. -Ctx concentrations of 	1 M were
applied to the oocyte by continuous perfusion, and the ACh
responses in the presence of the -Ctxs were normalized to the
average of at least three control responses. -Ctxs were applied
only after the ACh response-to-response variation was 10%.
The variance of the responses is provided as the S.D. and
shown with error bars. -Ctxs were routinely retested on
oocytes from different donors to ensure data reproducibility.
To estimate the IC50 value for inhibition of the ACh responses
by a given -Ctx, the normalized data were analyzed by nonlin-
ear regression and fit using a four-parameter logistic equation
in Prism (RRID:SCR_002798) (GraphPad Software Inc., La
Jolla, CA). The IC50 values are presented with corresponding
95% confidence intervals to evaluate the precision of the IC50
estimate. Although in many cases, the confidence intervals are
nonoverlapping, for the purposes of this study, the difference
between two IC50 values is considered significant if 3-fold.
For -Ctx–receptor combinations where inhibition by the
maximal -Ctx concentration tested was less than 40%, the
response after a 5-min static bath exposure to 10M -Ctx was
compared with control response, and the means were com-
pared using a one-way analysis of variance and Fisher’s least
significant difference to determine significance. Significance
was determined at the 95% level (p  .05). Concentration–
response curves for activation of nAChRs were obtained
according to the following procedures. ACh was applied in
ascending concentrations, and the current amplitudes for each
individual oocyte were analyzed by nonlinear regression and fit
using a four-parameter logistic equation in Prism to obtain the
calculated plateau value for activation. All ACh-evoked
responses were then normalized to the calculated plateau value
to obtain a percentage response and then analyzed with the
same four-parameter logistic equation.Data for theACh curves
were collected using oocytes from three different donors to
ensure reproducibility. Acetylcholine chloride (catalog no.
A6625), potassium chloride (catalog no. P3911), and BSA (cat-
alog no. A2153) were purchased from Sigma-Aldrich. Sodium
chloride (catalog no. S271), calcium chloride dihydrate (catalog
no. C79), magnesium chloride hexahydrate (catalog no. M33),
sodium hydroxide (catalog no. S313), and HEPES (catalog no.
BP310) were purchased from Fisher Scientific.
Site-directedmutagenesis of6/3 and4 subunits
cDNAs for human 6/3 and human and rat 4 subunits in
the pGEMHE vector were used as starting templates. cDNAs
for rat 6/3 were in the pT7TS vector. Oligonucleotide prim-
ers were designed to individually span positions 177 of the
6/3 subunit and 110, 118, and 119 of the 4 subunit and
included nucleotide substitutions to mutate each respective
amino acid residue. The double mutant constructs were made
using a single primer pair thatmutated positions 118 and 119 in
the same PCR. All oligonucleotides were synthesized by the
DNA/Peptide Facility, part of theHealth SciencesCenter Cores
at the University of Utah. Pfu Turbo (catalog no. 600250) DNA
polymerase (Agilent Technologies, Santa Clara, CA) was used
to extend the primers. The PCR conditions were as follows:
95 °C for 120 s for denaturation followed by 30 cycles of 95 °C
for 30 s, 65–78 °C (depending on the primers used) for 7 min,
72 °C for 60 s, and a final extension step for 10min at 72 °C. The
reaction was then digested with DpnI (catalog no. R0176S) to
remove template cDNA (New England Biolabs, Ipswich, MA).
Chemically competent DH5 (New England Biolabs, catalog
no. C2987I) or 10- (New England Biolabs, catalog no. C3019I)
cells were used for transformation. The cells were grown at
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37 °C for 1 h after transformation and then plated on agar plates
containing ampicillin and maintained at 37 °C overnight. Sev-
eral colonies were selected from each plate and individually
grown overnight at 37 °C in Luria–Bertani medium containing
ampicillin (Fisher Scientific, catalog no. BP1760). cDNA was
isolated from the cells using a Qiaprep Spin Miniprep Kit (cat-
alog no. 27104) (Qiagen, Valencia, CA) followed by sequencing
at the University of Utah DNA Sequencing Core Facility to
verify incorporation of themutations. cDNAs for human6/3
and human and rat 4 were linearized overnight at 37 °C using
the restriction enzyme NheI (New England Biolabs, catalog no.
R0131S), and rat 6/3 cDNA was linearized using SalI (New
England Biolabs, catalog no. R0138T) using the same protocol.
Following linearization, the cDNAs were purified and eluted with
water using the Qiaquick PCR purification kit (Qiagen, catalog
no. 28104). cRNA was then prepared from the linearized cDNA
using Ambion’s mMESSAGEmMACHINE T7 Transcription Kit
(Fisher Scientific, catalog no. AM1344) and purified using a Qia-
gen RNeasyMini Kit (Qiagen, catalog no. 74104).
Peptide synthesis
The synthesis of -Ctxs TxIB, [P13Q]PeIA, and [P13R]PeIA
was performed according tomethods described previously (40).
Synthesis of -Ctxs PnIA, PeIA, [P13A]PeIA, and [P13O]PeIA
was performed as described by Cartier et al. (50). Correct syn-
thesis of [P13Q]PeIA and [P13R]PeIA was verified by matrix-
assisted laser desorption TOF MS. The calculated monoiso-
topic masses for [P13Q]PeIA and [P13R]PeIA are 1682.63 and
1710.67 Da, and the observedmasses were 1682.74 and 1710.81
Da, respectively.
X-ray crystallography
The AChBP from A. californica was expressed and purified
as described previously (51, 52). Briefly, AChBP was expressed
with an N-terminal FLAG epitope tag and secreted from stably
transfected human embryonic kidney 293S cells lacking the
N-acetyglucosaminyltransferase I (GnTI) gene (53). The pro-
tein was purified with FLAG antibody resin and eluted with
FLAG peptide (Sigma-Aldrich, catalog no. F3290). Affinity-puri-
fied protein was further characterized by size-exclusion chroma-
tography in a Superdex 200 16/60 gel filtration column (GE
Healthcare) in 25mMTris-HCl (pH7.4), 150mMNaCl, and 0.02%
NaN3 (w/v). From this process, the pentameric association could
be ascertained, and monomeric subunits and trace contaminants
could be removed. Purified AChBP pentamers were then concen-
trated using a Millipore YM50 Centricon ultrafiltration unit
(Fisher Scientific) to a final concentration of5mg/ml.
Complex formation and crystallization
The PeIA–AChBP complex was formed by dissolving 10
mol of lyophilized PeIA with 50 l of purified and concen-
trated protein at a concentration of 5mg/ml. ThePeIA–AChBP
complex co-crystals were obtained by the vapor-diffusion
hanging-drop method. Concentrated protein complex was
mixed in a 1 l:1 l solution consisting of 0.1 M Tris-HCl (pH
8.0), 0.25MMgCl2, 20% (w/v) PEG4000, incubated at 22 °C, and
suspended over 500 l of the same solution. Crystals of 0.3 	
0.3	 0.2 mm final size appeared after a few weeks.
X-ray diffraction data collection
PeIA–AChBP complex co-crystals were transferred to a
cryoprotectant solution consisting of 0.1 M Tris-HCl (pH 8.0),
0.25 M MgCl2, 12% (w/v) PEG 4000, and 10% (v/v) glycerol and
flash-cooled in liquid nitrogen. A full set of X-ray diffraction data
werecollectedat278 °Catbeamline8.2.1 (AdvancedLightSource,
Berkeley, CA). Diffraction data were processed and scaled using
HKL2000 (54). Final data statistics are given in Table S1.
Structure refinement
The PeIA–AChBP complex structure was solved by the
molecular replacement method using PHASER (55) using the
AChBP/-Ctx BuIA structure (PDB entry 4EZ1) as a search
model. The electron density maps were manually fitted in
COOT (56) with iterative structure refinement done using phe-
nix.refine (RRID:SCR_014224) (57), resulting in a final model
with Rwork and Rfree of 19.6 and 22.8%, respectively. Refinement
statistics are listed in Table S1. Atomic coordinates and struc-
ture factors have been deposited in the PDB (entry 5JME). Car-
toon representations of the structures were generated using
PyMOL (RRID:SCR_000305) (58). It should be noted that
there was density for a fifth PeIA in the data obtained. How-
ever, although the density clearly showed the position of the
peptide backbone, it was not sufficient for accurate position-
ing of the side chains. Out of an abundance of caution, it was
decided to omit the final toxin chain to avoid any possible
misinterpretation.
NMR spectroscopy and structure calculations
Peptide samples (1.0 mg) were dissolved in 550 l of 10%
D2O, 90%H2O (pH3), and spectrawere recorded on a Bruker
Advance III 600-MHz spectrometer equipped with a cryo-
probe.Datawere collected at 290KusingTOCSY,NOESYH-N
HSQC, and H-C HSQC experiments. Spectra were acquired
with mixing times of 80 ms (TOCSY) or 200 ms (NOESY) and
4,096 data points in F2 and 512 in F1. Chemical shifts were
referenced to internal 2,2-dimethyl-2-silapentane-5-sulfonate
at 0 ppm. Spectra were processed with Topspin version 3.5
(Bruker Biospin) and assigned using the program CcpNmr
Analysis (59). Structure calculations of [P13A]PeIA were based
upon distance restraints derived from NOESY spectra and on
backbone dihedral angle restraints generated using TALOS
(60). A family of 20 lowest-energy structures consistent with
the experimental restraints was calculated using CYANA (61)
and assessed using Molprobity (RRID:SCR_014226) (62).
Experimental restraints and stereochemical quality assessment
outcomes are provided in Table S2.
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